RxDoctor Payments Data

David Gehring, MD

Internal Medicine · Woodbury, NJNPI 1740288091

Payments from drug & device makers

$653in general payments, 2019–2025

Across 44 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$67
  • Novo Nordisk$65
  • Exact Sciences$63
  • Lilly USA, LLC$55
  • Pfizer$55
  • Astellas Pharma US Inc$43
  • plus $305 from 15 others

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,370
Medicare patients
398
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$158,750
JanuviaSitagliptin Phosphate69$101,797
AustedoDeutetrabenazine11$79,246
JardianceEmpagliflozin51$76,075
TrulicityDulaglutide44$75,539
EliquisApixaban75$75,388
TradjentaLinagliptin65$69,206
OzempicSemaglutide34$66,092
FarxigaDapagliflozin Propanediol41$48,786
XareltoRivaroxaban38$38,187
RexultiBrexpiprazole20$34,187
MyrbetriqMirabegron31$33,243
Tresiba Flextouch U-200Insulin Degludec18$23,725
Breo ElliptaFluticasone/Vilanterol57$23,378
VascepaIcosapent Ethyl30$20,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$55$234,288139 claims
MerckJanuvia$34$101,79769 claims
PfizerEliquis$55$75,38875 claims
Novo NordiskOzempic$65$66,09234 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$67$55,699101 claims
AstraZenecaFarxiga, Symbicort$42$54,71561 claims
Johnson & JohnsonXarelto$13$38,18738 claims
Astellas Pharma US IncMyrbetriq$43$33,24331 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$12,89917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →